The first patients have been dosed in a phase 2 clinical trial investigating Brimochol for the treatment of presbyopia, according to a press release from Visus Therapeutics.
The double-masked, randomized crossover trial is investigating the safety and efficacy of two formulations of Brimochol topical ophthalmic solution (carbachol and brimonidine tartrate) in patients with emmetropic phakic and pseudophakic presbyopia, the release said. About 42 patients will be enrolled in the 30-day trial.
“By combining the unique properties of carbachol and brimonidine tartrate into one novel eye drop,
Uncategorized